CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Trial end date:
2017-08-07
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of T cells
that can be given in combination with standard chemotherapy to patients with CLL. The safety
of this combination will also be studied.
The T cells being used in this study are a type of white blood cell that will be taken from
your blood and then genetically changed in a laboratory. The process of changing the DNA (the
genetic material of cells) of the T cells is called a gene transfer. After the gene transfer
is complete, the genetically changed T-cells will be put back into your body. These T cells
may help prevent cancer cells from coming back.